Table 2

Pre-treatment demographic and clinical characteristic of study participants

Intention to Treat

Study Completer


NET (n = 16)

WLC (n = 18)

p

NET (n = 11)

WLC (n = 8)

p


Demographic Data

Sex

0.97

0.31

female

N (%)

7 (43.8)

8 (44.4)

3 (27.3)

4 (50.0)

male

N (%)

9 (56.3)

10 (55.6)

8 (72.7)

4 (50.0)

Age

M (SD)

30.3 (9.2)

36.4 (9.9)

0.09

28.6 (8.6)

33.6 (9.8)

0.25

Education (ys school)

M (SD)

8.7 (3.3)

7.8 (3.3)

0.51

8.9 (3.4)

7.9 (2.7)

0.51

Regions of Origin

0.15

0.65

Middle East

N (%)

8 (50.0)

11 (61.1)

6 (54.6)

4 (50.0)

Central East

N (%)

2 (12.5)

1 (5.6)

1 (9.1)

1 (12.5)

The Balkans

N (%)

-

3 (16.7)

-

1 (12.5)

Africa

N (%)

6 (37.5)

2 (11.1)

4 (36.4)

2 (25.0)

Asylum Status (insecure)

N (%)

14 (87.5)

18 (100.0)

0.12

9 (81.8)

8 (100.0)

0.20


Clinical Data

Events (numbers)

CAPS Event-Types

M (SD)

7.4 (2.3)

6.6 (2.0)

0.31

7.0 (2.3)

6.5 (2.1)

0.71

War&Torture-Types

M (SD)

11.3 (5.6)

9.4 (4.7)

0.29

11.4 (6.7)

7.6 (4.9)

0.16

Clinical Symptoms

CAPS Score

M (SD)

89.5 (14.7)

80.1 (16.5)

0.16

88.0 (12.5)

72.0 (13.8)

0.04

HDRS

M (SD)

27.3 (8.1)

27.3 (6.9)

0.74

25.8 (7.9)

27.4 (5.6)

0.77


Study Completers were called only those participants, who completed therapy and produced MEG data sets (pre and post) of good quality that could be included in the final analysis.

Note: For pair-wise group comparisons of continuous variables, Mann-Whitney U Tests were used; differences of categorical variables were evaluated by applying χ2-Tests for independence.

Adenauer et al. BMC Neuroscience 2011 12:127   doi:10.1186/1471-2202-12-127

Open Data